ArticleThe Journal of veterinary medical science2025
Assessment of gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid coating for treating dry eye associated keratopathy in rats.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polyphenol-Loaded Nanodevices as Innovative Therapeutic Strategies for Dry Eye Disease: Advances and Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconjunctivitis sicca (KCS) is a common ocular disease in dogs characterized by inflammation of the cornea and conjunctiva. This study investigates the effectiveness of gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid coating (GEH NPs) and various artificial tears in treating KCS led keratopathy in a rat model. Eighteen female Sprague-Dawley rats, aged 6 to 8 weeks were randomly assigned to 6 groups of 3. All rats except the Sham group underwent unilateral exorbital and infraorbital lacrimal gland excisions to induce KCS. The treatment groups included a KCS group without treatment, a GEH group treated with GEH NPs, and 3 groups receiving different artificial tears. Clinical examinations, including slit-lamp biomicroscopy, optical coherence tomography (OCT), and ocular surface analyser-VET (OSA-VET) were conducted preoperatively at 1 and 2 weeks postoperatively. For treating KCS associated keratopathy, the GEH NPs showed superior outcomes and consistently ranked among the strongest treatment options in most aspects evaluated, including reduced corneal irregularity, improved tear film stability, and lower fluorescein scores, indicating better corneal integrity. Additionally, the GEH group displayed the least inflammatory cell infiltration and maintained a healthier epithelial structure, further underscoring its protective effects. GEH was administered twice daily while other treatment groups were administrated 3 times daily, highlighting its efficacy even with a lower dosing frequency. The artificial tears demonstrated variable benefits on KCS led keratopathy across different evaluations. GEH NPs exhibited excellent protective effects and therapeutic potential on dry eye associated keratopathy based on this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.